Genentech Licenses DualityBio's Next-Gen ADC Payload Platform to Counter TOPO1 Resistance
- Genentech has licensed DualityBio's DUPAC antibody-drug-conjugate payload platform: $45M upfront, over $1B in milestones, plus tiered royalties.
- Shanghai-based DualityBio handles target-specific ADC discovery through Phase 1a on Genentech-chosen oncology targets; Genentech then owns exclusive rights through late-stage development and commercialization.
- The rationale is payload resistance — topoisomerase-1 (TOP1) inhibitor payloads underpin most current ADCs, including DualityBio's own BioNTech-partnered HER2 asset, and resistance is rising as these drugs reach earlier treatment lines.
- DUPAC is pitched as a next-gen payload that stays active in TOP1-resistant tumors.
- This follows DualityBio's 2023 BioNTech deal (>$1.5B) and extends MNC pharma's pattern of sourcing ADC payload innovation from China.
The economics: $45M upfront against $1B+ in milestones is a cheap call option for Genentech — DualityBio absorbs discovery and Phase 1a risk, and Genentech only pays once DUPAC clears its resistance hurdle. That's a smaller headline number than DualityBio's 2023 BioNTech deal, hinting at either narrower scope or softer terms on partner #2. Strategically, this is Roche/Genentech hedging against a class-wide ceiling: TOP1 payloads underpin nearly the entire current ADC generation, including Enhertu and DualityBio's own BioNTech HER2 asset, so resistance will bite everyone eventually. It also confirms Genentech won't build payload discovery in-house, joining Pfizer/Seagen and AbbVie/ImmunoGen in sourcing ADC innovation from China. For DualityBio, a second nine-figure MNC partner in three years validates the platform model — though whether DUPAC actually beats resistant tumors is still unproven.
Roche bets $1B+ on DualityBio's ADC tech to tackle TOPO1 resistance ↗